Exciting advancements in peanut oral immunotherapy have extended relief to adult patients, showcasing the potential for future research in this field. A study involving 18 patients in the primary efficacy population and 21 in the intention to treat analysis demonstrated promising results. A significant proportion of patients were able to tolerate substantial doses of peanut protein, with 78% meeting the primary end point by tolerating at least 1.4 g and 67% of the intention to treat population achieving the same. The median highest tolerated dose saw a remarkable increase from 30 mg to 3000 mg at the exit challenge, indicating a 100-fold improvement (P< .0001). Moreover, 56% of the primary efficacy population successfully met the secondary end point of tolerating a cumulative dose of 4.4 g peanut protein, with 48% in the intention to treat group also reaching this milestone. These findings not only highlight the efficacy of peanut oral immunotherapy in adults but also underscore the importance of further research in optimizing treatment strategies for peanut allergies.
Read more about this — here
